Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study

详细信息	查看全文 | 推荐本文 |

• 作者：Angelo Iacobellis ; Massimo Siciliano ; Francesco Perri ; Brigida E. Annicchiarico ; Gioacchino Le ; ro ; Nazario Caruso ; Laura Accadia ; Giuseppe Bombardieri ; Angelo Andriulli
• 刊名：Journal of Hepatology
• 出版年：2007
• 期刊代码：162_01688278
• 类别：med
• 出版时间：February 2007
• 卷：46
• 期：2
• 页码：206-212
• 文件大小：129 K

摘要

Background/Aim

To evaluate long-term outcomes in decompensated HCV-related cirrhotic patients treated with antiviral therapy.

Methods

Of 129 eligible patients, 66 received peginterferon alfa-2b and ribavirin for 24 weeks, and 63 were controls. Survival and recurrence of liver failure events after therapy were main outcomes.

Results

Therapy was tolerated by 27 patients, dose reduced in 26 for toxicity, and discontinued in 13 for intolerance. End-of-therapy and sustained virological response (SVR) rates were 82.6%and 43.5%for HCV 2/3 patients, and 30.2%and 7.0%for HCV 1/4 patients. During therapy, odds ratios for severe infections or deaths due to infection were 2.95 (95%C.I. 0.93–9.3) and 1.97 (95%C.I. 0.40–9.51) in treated patients as compared with controls. During a follow-up of 30 months off-therapy, decompensated events occurred in 52, 33, and 3 of controls, non-responders, and SVR patients. Odds ratios for ascites, encephalopathy, and oesophageal bleeding in treated patients significantly decreased as compared with controls. Annualized incidence of death was 2.34, 1.91, and 0 per 1000 patient-years, respectively, in controls, non-responders, and SVR patients. Survival curves showed early separation of SVR patients from both non-responders and controls at approximately 6 months.

Conclusions

In decompensated cirrhotics, HCV clearance by therapy is life-saving and reduces disease progression.